Experience of cancer care for metastasis-induced acute pancreatitis patients with lung cancer.
BACKGROUND
Little information is available concerning the prognosis and treatment of metastasis-induced acute pancreatitis (MIAP) with lung cancer. The aim of this study was to investigate the prognostic factors of MIAP patients with lung cancer.


METHODS
A retrospective study of 20 MIAP patients with lung cancer was performed. Survival was estimated using Kaplan-Meier method. Prognostic factors were assessed with Cox proportional hazards regression model.


RESULTS
There were 14 men and six women; 15 cases were non-small cell lung cancer and five cases were small cell lung cancer. The median age was 68 (range, 41-83). The mean duration from lung cancer to MIAP diagnosis of having MIAP was 139.8 days (range, 3-892). However, two small cell lung cancer cases had preceded presentation with acute pancreatitis. Chemotherapy (p = 0.008; hazards ratio = 4.99; 95% confidence interval = 1.51-16.54) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) (p = 0.007; hazards ratio = 6.13; 95% confidence interval = 0.04-0.61) were significant prognostic factors for survival. ECOG PS 3 to 4 at diagnosis of MIAP was 11/20. Survival of MIAP with lung cancer was 108.7 days. Patients with ECOG PS 3 to 4 had shorter mean survival than those with PS 0 to 2 (33.7 versus 226.4 days; p = 0.003). Chemotherapy group had longer mean survival than those without chemotherapy (161.9 versus 25.0 days; p = 0.01).


CONCLUSIONS
Chemotherapy can improve survival of MIAP from bronchogenic carcinoma in the selected patients.
Liu
Shih-Feng
SF
Division of Pulmonary and Critical Care Medicine and Respiratory Therapy, Department of Internal Medicine, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung Hsien, Taiwan.
Zhang
Shu
S
Chen
Yung-Che
YC
Fang
Wen-Feng
WF
Lin
Meng-Chih
MC
Su
Mao-Chang
MC
Wang
Chin-Chou
CC
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D001932:Brain Neoplasms / Q000556:secondary / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000556:secondary*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000556:secondary*; D010195:Pancreatitis / Q000188:drug therapy* / Q000209:etiology*; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000556:secondary*; D015996:Survival Rate; D016896:Treatment Outcome